The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 22, 2022
Filed:
Apr. 07, 2017
Applicant:
Immunocore Limited, Abingdon, GB;
Inventors:
Conor Hayes, Abingdon, GB;
Linda Hibbert, Abingdon, GB;
Nathaniel Ross Liddy, Abingdon, GB;
Tara Mahon, Abingdon, GB;
Marine Raman, Abingdon, GB;
Assignee:
IMMUNOCORE LIMITED, Abingdon, GB;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/725 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); C12N 15/62 (2006.01);
U.S. Cl.
CPC ...
C07K 14/7051 (2013.01); A61P 35/00 (2018.01); C07K 16/2833 (2013.01); C07K 16/30 (2013.01); C12N 15/62 (2013.01); C07K 2317/56 (2013.01); C07K 2317/64 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01); C07K 2319/035 (2013.01);
Abstract
The present invention relates to T cell receptors (TCRs) that bind the HLA-A*02 restricted peptide GVYDGREHTV (SEQ ID NO: 1) derived from the germline cancer antigen MAGE A4. Said TCRs may comprise non-natural mutations within the alpha and/or beta variable domains relative to a native MAGE A4 TCR. The TCRs of the invention are particularly suitable for use as novel immunotherapeutic reagents for the treatment of malignant disease.